Xycrobe technology targets certain skin conditions and cosmetic treatments using an isolated live strain of skin-relevant bacteria, according to Crown, the fast-growing Johnson City, TN-based skin health company.
Xycrobe technology harnesses the power of a particular strain of Cutibacterium acnes subspecies defenders (C. acnes defenders), a subspecies of the most prolific skin-specific bacterial species, accounting for an average of 89% of the bacteria in the sebaceous follicles of the skin, to improve the health and appearance of the skin by healing and supporting proper tension within the existing microbiome.
Recently published study results demonstrate that Crown’s Biojuve regimen, incorporating the Xycrobe strain and its ferment, supports a healthy skin environment, promotes increased skin hydration, reduces redness, regulates sebum production and reduces the appearance of the signs of aging. such as fine lines and photodamage.
Biojuve is a new regimen of dermatologist-dispensed products currently in soft launch now. The range is expected to go on sale in 2023 and will be sold by the Crown Aesthetics team in the US, according to company officials.
“The research we present in this article debunks numerous myths that have been perpetuated over the last half-century or so about what constitutes a healthy skin microbiome, what role C. acnes strains play in skin health, and the ability to formulate progressive topicals with live microbes that could contribute to an overall healthier skin biome,” said Thomas M. Hitchcock, MD, PhD, Chief Scientific Officer, Crown Laboratories Inc. “We strongly believe that Crown Laboratories Inc. is a pioneer in the “skin biome care” category with our extensive research in the skin biome Our goal is to continue to invest in exploring the relationship between the microbes that live on and in the skin, and how it is A new philosophy of formulating topicals to holistically consider the skin biome may change the way we care for skin.”
“Traditionally, the medical approach to topical skin care products has always focused on how a given ingredient may affect the overall health of skin cells with minimal consideration of how the ingredients affect the microflora or microbiome. of the skin,” added Dr. Doris Day, Board. Board-certified dermatologist and research study participant. “The proven efficacy of this proprietary Xycrobe technology reinforces the idea that the human body is dependent on symbiosis. I anticipate this research will diversify the way clinicians approach health and treatment of skin conditions.”
Subjects in this eight-week study used a 5- or 7-point Likert scale (agree/none/disagree) over a two-month testing period. Concordance responses at or above the 90th percentile included (improved) skin texture, tone, healthy and natural appearance, felt conditioned, radiant, and vibrant (n=121*).
The full study on the effectiveness of Xycrobe along with the findings have been made available to the public.